AAAAAA

   
Results: 1-25 | 26-44
Results: 1-25/44
DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY
Authors: DEJONG JLO FARNER NL JAVORSKY BR LINDSTROM MJ HANK JA SONDEL PM
Citation: Jlo. Dejong et al., DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY, Clinical cancer research, 4(5), 1998, pp. 1287-1296
DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY
Authors: DEJONG JLO FARNER NL JAVORSKY BR LINDSTROM MJ HANK JA SONDEL PM
Citation: Jlo. Dejong et al., DIFFERENTIAL QUANTITATIVE EFFECTS OF INTERLEUKIN (IL)-2 AND IL-15 ON CYTOTOXIC ACTIVITY AND PROLIFERATION BY LYMPHOCYTES FROM PATIENTS RECEIVING IN-VIVO IL-2 - THERAPY, Clinical cancer research, 4(5), 1998, pp. 1287-1296
FEASIBILITY, TOXICITY, AND BIOLOGIC RESPONSE OF INTERLEUKIN-2 AFTER CONSOLIDATION CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA - A REPORT FROM THE CHILDRENS CANCER GROUP
Authors: SIEVERS EL LANGE BJ SONDEL PM KRAILO MD GAN J LIUMARES W FEIG SA
Citation: El. Sievers et al., FEASIBILITY, TOXICITY, AND BIOLOGIC RESPONSE OF INTERLEUKIN-2 AFTER CONSOLIDATION CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA - A REPORT FROM THE CHILDRENS CANCER GROUP, Journal of clinical oncology, 16(3), 1998, pp. 914-919
TRANSCRIPTION FACTOR ACTIVATION IN LYMPHOKINE-ACTIVATED KILLER-CELLS AND LYMPHOCYTES FROM PATIENTS RECEIVING IL-2 IMMUNOTHERAPY
Authors: NICOLET CM SURFUS JM HANK JA SONDEL PM
Citation: Cm. Nicolet et al., TRANSCRIPTION FACTOR ACTIVATION IN LYMPHOKINE-ACTIVATED KILLER-CELLS AND LYMPHOCYTES FROM PATIENTS RECEIVING IL-2 IMMUNOTHERAPY, Cancer immunology and immunotherapy, 46(6), 1998, pp. 327-337
COMBINATION THERAPY WITH INTERLEUKIN-2 AND ANTITUMOR MONOCLONAL-ANTIBODIES
Authors: SONDEL PM HANK JA
Citation: Pm. Sondel et Ja. Hank, COMBINATION THERAPY WITH INTERLEUKIN-2 AND ANTITUMOR MONOCLONAL-ANTIBODIES, The cancer journal from Scientific American, 3, 1997, pp. 121-127
PHASE IB TRIAL OF CHIMERIC ANTIDISIALOGANGLIOSIDE ANTIBODY PLUS INTERLEUKIN-2 FOR MELANOMA PATIENTS
Authors: ALBERTINI MR HANK JA SCHILLER JH KHORSAND M BORCHERT AA GAN J BECHHOFER R STORER B REISFELD RA SONDEL PM
Citation: Mr. Albertini et al., PHASE IB TRIAL OF CHIMERIC ANTIDISIALOGANGLIOSIDE ANTIBODY PLUS INTERLEUKIN-2 FOR MELANOMA PATIENTS, Clinical cancer research, 3(8), 1997, pp. 1277-1288
ALTERATION OF THE CD34(-1-BETA CELL-LINE PROFILE IN RESPONSE TO LONG-TERM EXPOSURE TO IL-15() TF)
Authors: FARNER NL GAN J DEJONG JLO LEARY TP FENSKE TS BUCKLEY P DUNLAP S SONDEL PM
Citation: Nl. Farner et al., ALTERATION OF THE CD34(-1-BETA CELL-LINE PROFILE IN RESPONSE TO LONG-TERM EXPOSURE TO IL-15() TF), Cytokine, 9(5), 1997, pp. 316-327
PHASE I IB STUDY OF IMMUNIZATION WITH AUTOLOGOUS TUMOR-CELLS TRANSFECTED WITH THE GM-CSF GENE BY PARTICLE-MEDIATED TRANSFER IN PATIENTS WITH MELANOMA OR SARCOMA/
Authors: MAHVI DM SONDEL PM YANG NS ALBERTINI MR SCHILLER JH HANK J HEINER J GAN J SWAIN W LOGRONO R
Citation: Dm. Mahvi et al., PHASE I IB STUDY OF IMMUNIZATION WITH AUTOLOGOUS TUMOR-CELLS TRANSFECTED WITH THE GM-CSF GENE BY PARTICLE-MEDIATED TRANSFER IN PATIENTS WITH MELANOMA OR SARCOMA/, Human gene therapy, 8(7), 1997, pp. 875-888
TAG-72-REACTIVE ANTIBODY CC49 RECOGNIZES MOLECULES EXPRESSED BY HEMATOPOIETIC-CELL LINES
Authors: NICOLET CM SIEGEL DH SURFUS JE SONDEL PM
Citation: Cm. Nicolet et al., TAG-72-REACTIVE ANTIBODY CC49 RECOGNIZES MOLECULES EXPRESSED BY HEMATOPOIETIC-CELL LINES, Tumor biology, 18(6), 1997, pp. 356-366
RESULTS OF ALLOGENEIC BONE-MARROW TRANSPLANTS FOR LEUKEMIA USING DONORS OTHER THAN HLA-IDENTICAL SIBLINGS
Authors: SZYDLO R GOLDMAN JM KLEIN JP GALE RP ASH RC BACH FH BRADLEY BA CASPER JT FLOMENBERG N GAJEWSKI JL GLUCKMAN E HENSLEEDOWNEY PJ HOWS JM JACOBSEN N KOLB HJ LOWENBERG B MASAOKA T ROWLINGS PA SONDEL PM VANBEKKUM DW VANROOD JJ VOWELS MR ZHANG MJ HOROWITZ MM
Citation: R. Szydlo et al., RESULTS OF ALLOGENEIC BONE-MARROW TRANSPLANTS FOR LEUKEMIA USING DONORS OTHER THAN HLA-IDENTICAL SIBLINGS, Journal of clinical oncology, 15(5), 1997, pp. 1767-1777
A PHASE I IB TRIAL OF MURINE MONOCLONAL ANTI-GD2 ANTIBODY 14.G2A PLUSINTERLEUKIN-2 IN CHILDREN WITH REFRACTORY NEUROBLASTOMA - A REPORT OFTHE CHILDRENS CANCER GROUP/
Authors: FROST JD HANK JA REAMAN GH FRIERDICH S SEEGER RC GAN J ANDERSON PM ETTINGER LJ CAIRO MS BLAZAR BR KRAILO MD MATTHAY KK REISFELD RA SONDEL PM
Citation: Jd. Frost et al., A PHASE I IB TRIAL OF MURINE MONOCLONAL ANTI-GD2 ANTIBODY 14.G2A PLUSINTERLEUKIN-2 IN CHILDREN WITH REFRACTORY NEUROBLASTOMA - A REPORT OFTHE CHILDRENS CANCER GROUP/, Cancer, 80(2), 1997, pp. 317-333
CLINICAL AND IMMUNOLOGICAL EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR COADMINISTERED WITH INTERLEUKIN-2 - A PHASE IB STUDY
Authors: SCHILLER JH HANK JA KHORSAND M STORER B BORCHERT A HUSEBYMOORE K BURNS D WESLY O ALBERTINI MR WILDING G SONDEL PM
Citation: Jh. Schiller et al., CLINICAL AND IMMUNOLOGICAL EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR COADMINISTERED WITH INTERLEUKIN-2 - A PHASE IB STUDY, Clinical cancer research, 2(2), 1996, pp. 319-330
ACTIVATION OF HUMAN EFFECTOR-CELLS BY A TUMOR REACTIVE RECOMBINANT ANTIGANGLIOSIDE GD(2) INTERLEUKIN-2 FUSION PROTEIN (CH14.18-IL2)
Authors: HANK JA SURFUS JE GAN JC JAEGER P GILLIES SD REISFELD RA SONDEL PM
Citation: Ja. Hank et al., ACTIVATION OF HUMAN EFFECTOR-CELLS BY A TUMOR REACTIVE RECOMBINANT ANTIGANGLIOSIDE GD(2) INTERLEUKIN-2 FUSION PROTEIN (CH14.18-IL2), Clinical cancer research, 2(12), 1996, pp. 1951-1959
SYSTEMIC INTERLEUKIN-2 MODULATES THE ANTIIDIOTYPIC RESPONSE TO CHIMERIC ANTI-GD2 ANTIBODY IN PATIENTS WITH MELANOMA
Authors: ALBERTINI MR GAN J JAEGER P HANK JA STORER B SCHELL K RIVEST T SURFUS J REISFELD RA SCHILLER JH SONDEL PM
Citation: Mr. Albertini et al., SYSTEMIC INTERLEUKIN-2 MODULATES THE ANTIIDIOTYPIC RESPONSE TO CHIMERIC ANTI-GD2 ANTIBODY IN PATIENTS WITH MELANOMA, Journal of immunotherapy with emphasis on tumor immunology, 19(4), 1996, pp. 278-295
ANTI-RENAL-CELL CARCINOMA CHIMERIC ANTIBODY G250 FACILITATES ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY WITH IN-VITRO AND IN-VIVO INTERLEUKIN-2-ACTIVATED EFFECTORS
Authors: SURFUS JE HANK JA OOSTERWIJK E WELT S LINDSTROM MJ ALBERTINI MR SCHILLER JH SONDEL PM
Citation: Je. Surfus et al., ANTI-RENAL-CELL CARCINOMA CHIMERIC ANTIBODY G250 FACILITATES ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY WITH IN-VITRO AND IN-VIVO INTERLEUKIN-2-ACTIVATED EFFECTORS, Journal of immunotherapy with emphasis on tumor immunology, 19(3), 1996, pp. 184-191
PARTICLE-MEDIATED GENE-TRANSFER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR CDNA TO TUMOR-CELLS - IMPLICATIONS FOR A CLINICALLY RELEVANT TUMOR VACCINE
Authors: MAHVI DM BURKHOLDER JK TURNER J CULP J MALTER JS SONDEL PM YANG NS
Citation: Dm. Mahvi et al., PARTICLE-MEDIATED GENE-TRANSFER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR CDNA TO TUMOR-CELLS - IMPLICATIONS FOR A CLINICALLY RELEVANT TUMOR VACCINE, Human gene therapy, 7(13), 1996, pp. 1535-1543
INTERLEUKIN-2 MEDIATED ACTIVATION OF JAK3 IN THE ABSENCE OF A DETECTABLE 64-KDA COMMON GAMMA-CHAIN
Authors: FENSKE TS FARNER NL DEJONG JLO OSHEA JJ SONDEL PM
Citation: Ts. Fenske et al., INTERLEUKIN-2 MEDIATED ACTIVATION OF JAK3 IN THE ABSENCE OF A DETECTABLE 64-KDA COMMON GAMMA-CHAIN, The FASEB journal, 10(6), 1996, pp. 1752-1752
GENE GUN-MEDIATED SKIN TRANSFECTION WITH INTERLEUKIN-12 GENE RESULTS IN REGRESSION OF ESTABLISHED PRIMARY AND METASTATIC MURINE TUMORS
Authors: RAKHMILEVICH AL TURNER J FORD MJ MCCABE D SUN WH SONDEL PM GROTA K YANG NS
Citation: Al. Rakhmilevich et al., GENE GUN-MEDIATED SKIN TRANSFECTION WITH INTERLEUKIN-12 GENE RESULTS IN REGRESSION OF ESTABLISHED PRIMARY AND METASTATIC MURINE TUMORS, Proceedings of the National Academy of Sciences of the United Statesof America, 93(13), 1996, pp. 6291-6296
INTERACTION OF IL-15 WITH THE SHARED IL-2 RECEPTOR-BETA AND GAMMA(C) SUBUNITS - THE IL-15 BETA/GAMMA(C) RECEPTOR-LIGAND COMPLEX IS LESS STABLE THAN THE IL-2/BETA/GAMMA(C) RECEPTOR-LIGAND COMPLEX/
Authors: DEJONG JLO FARNER NL WIDMER MB GIRI JG SONDEL PM
Citation: Jlo. Dejong et al., INTERACTION OF IL-15 WITH THE SHARED IL-2 RECEPTOR-BETA AND GAMMA(C) SUBUNITS - THE IL-15 BETA/GAMMA(C) RECEPTOR-LIGAND COMPLEX IS LESS STABLE THAN THE IL-2/BETA/GAMMA(C) RECEPTOR-LIGAND COMPLEX/, The Journal of immunology, 156(4), 1996, pp. 1339-1348
LYSIS OF HUMAN TUMOR-CELL LINES BY CANINE COMPLEMENT PLUS MONOCLONAL ANTIGANGLIOSIDE ANTIBODIES OR NATURAL CANINE XENOANTIBODIES
Authors: HELFAND SC HANK JA GAN J SONDEL PM
Citation: Sc. Helfand et al., LYSIS OF HUMAN TUMOR-CELL LINES BY CANINE COMPLEMENT PLUS MONOCLONAL ANTIGANGLIOSIDE ANTIBODIES OR NATURAL CANINE XENOANTIBODIES, Cellular immunology, 167(1), 1996, pp. 99-107
CLINICAL AND IMMUNOLOGICAL EFFECTS OF TREATMENT WITH MURINE ANTI-CD3 MONOCLONAL-ANTIBODY ALONG WITH INTERLEUKIN-2 IN PATIENTS WITH CANCER
Authors: HANK JA ALBERTINI M WESLY OH SCHILLER JH BORCHERT A MOORE K BECHHOFER R STORER B GAN J GAMBACORTI C SOSMAN J SONDEL PM
Citation: Ja. Hank et al., CLINICAL AND IMMUNOLOGICAL EFFECTS OF TREATMENT WITH MURINE ANTI-CD3 MONOCLONAL-ANTIBODY ALONG WITH INTERLEUKIN-2 IN PATIENTS WITH CANCER, Clinical cancer research, 1(5), 1995, pp. 481-491
X-LINKED SEVERE COMBINED IMMUNODEFICIENCY DISEASE AND THE GAMMA(C) RECEPTOR COMPONENT - PROSPECTS FOR MOLECULAR DIAGNOSIS
Authors: FARNER NL VOSS SD SONDEL PM
Citation: Nl. Farner et al., X-LINKED SEVERE COMBINED IMMUNODEFICIENCY DISEASE AND THE GAMMA(C) RECEPTOR COMPONENT - PROSPECTS FOR MOLECULAR DIAGNOSIS, Clinical and diagnostic laboratory immunology, 2(5), 1995, pp. 518-523
EXPRESSION OF A TUMOR-REACTIVE ANTIBODY-INTERLEUKIN-2 FUSION PROTEIN AFTER IN-VIVO PARTICLE-MEDIATED GENE DELIVERY
Authors: NICOLET CM BURKHOLDER JK GAN J CULP J KASHMIRI SVS SCHLOM J YANG NS SONDEL PM
Citation: Cm. Nicolet et al., EXPRESSION OF A TUMOR-REACTIVE ANTIBODY-INTERLEUKIN-2 FUSION PROTEIN AFTER IN-VIVO PARTICLE-MEDIATED GENE DELIVERY, Cancer gene therapy, 2(3), 1995, pp. 161-170
INTERFERON-ALPHA ENHANCES EXPRESSION OF TAG-72 AND CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH PRIMARY COLORECTAL-CANCER
Authors: MAHVI DM MADSEN JA WITT PL SONDEL PM
Citation: Dm. Mahvi et al., INTERFERON-ALPHA ENHANCES EXPRESSION OF TAG-72 AND CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH PRIMARY COLORECTAL-CANCER, Cancer immunology and immunotherapy, 40(5), 1995, pp. 311-314
A PHASE-II TRIAL OF HUMAN RECOMBINANT INTERLEUKIN-2 ADMINISTERED AS A4-DAY CONTINUOUS-INFUSION FOR CHILDREN WITH REFRACTORY NEUROBLASTOMA,NON-HODGKINS-LYMPHOMA, SARCOMA, RENAL-CELL CARCINOMA, AND MALIGNANT-MELANOMA - A CHILDRENS CANCER GROUP STUDY
Authors: BAUER M REAMAN GH HANK JA CAIRO MS ANDERSON P BLAZAR BR FRIERDICH S SONDEL PM
Citation: M. Bauer et al., A PHASE-II TRIAL OF HUMAN RECOMBINANT INTERLEUKIN-2 ADMINISTERED AS A4-DAY CONTINUOUS-INFUSION FOR CHILDREN WITH REFRACTORY NEUROBLASTOMA,NON-HODGKINS-LYMPHOMA, SARCOMA, RENAL-CELL CARCINOMA, AND MALIGNANT-MELANOMA - A CHILDRENS CANCER GROUP STUDY, Cancer, 75(12), 1995, pp. 2959-2965
Risultati: 1-25 | 26-44